Magainin Pharmaceuticals Inc. does not yet know whether the FDA will ask the company to run another trial for its Locilex pexiganan acetate to treat infected diabetic foot ulcers following the 7-4 vote against marketing approval by the agency's Anti-Infective Drugs Advisory Committee last week. But without Locilex, MAGN would be 3-4 years away from the market.

The company